1. Home
  2. VYGR vs EVC Comparison

VYGR vs EVC Comparison

Compare VYGR & EVC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • VYGR
  • EVC
  • Stock Information
  • Founded
  • VYGR 2013
  • EVC 1996
  • Country
  • VYGR United States
  • EVC United States
  • Employees
  • VYGR N/A
  • EVC N/A
  • Industry
  • VYGR Biotechnology: Pharmaceutical Preparations
  • EVC Broadcasting
  • Sector
  • VYGR Health Care
  • EVC Industrials
  • Exchange
  • VYGR Nasdaq
  • EVC Nasdaq
  • Market Cap
  • VYGR 222.9M
  • EVC 179.2M
  • IPO Year
  • VYGR 2015
  • EVC 2000
  • Fundamental
  • Price
  • VYGR $3.39
  • EVC $2.13
  • Analyst Decision
  • VYGR Strong Buy
  • EVC
  • Analyst Count
  • VYGR 9
  • EVC 0
  • Target Price
  • VYGR $14.86
  • EVC N/A
  • AVG Volume (30 Days)
  • VYGR 360.5K
  • EVC 486.1K
  • Earning Date
  • VYGR 03-11-2025
  • EVC 03-06-2025
  • Dividend Yield
  • VYGR N/A
  • EVC 9.57%
  • EPS Growth
  • VYGR N/A
  • EVC N/A
  • EPS
  • VYGR N/A
  • EVC N/A
  • Revenue
  • VYGR $80,001,000.00
  • EVC $364,948,000.00
  • Revenue This Year
  • VYGR N/A
  • EVC $64.06
  • Revenue Next Year
  • VYGR $23.46
  • EVC N/A
  • P/E Ratio
  • VYGR N/A
  • EVC N/A
  • Revenue Growth
  • VYGR N/A
  • EVC 22.86
  • 52 Week Low
  • VYGR $3.56
  • EVC $1.58
  • 52 Week High
  • VYGR $10.66
  • EVC $2.73
  • Technical
  • Relative Strength Index (RSI)
  • VYGR 28.74
  • EVC 52.14
  • Support Level
  • VYGR $3.58
  • EVC $2.05
  • Resistance Level
  • VYGR $3.96
  • EVC $2.27
  • Average True Range (ATR)
  • VYGR 0.25
  • EVC 0.12
  • MACD
  • VYGR -0.01
  • EVC 0.03
  • Stochastic Oscillator
  • VYGR 2.60
  • EVC 74.00

About VYGR Voyager Therapeutics Inc.

Voyager Therapeutics Inc is a gene therapy company focused on developing life-changing treatments for patients suffering from severe neurological diseases. It focuses on neurological diseases where an adeno-associated virus, or AAV, gene therapy approach that either increases or decreases the production of a specific protein can slow or reduce the symptoms experienced by patients, and therefore have a clinically meaningful impact. The company's gene therapy platform TRACER enables to engineer, optimize, manufacture and deliver AAV-based gene therapies that have the potential to provide durable efficacy following a single administration. Its pipeline of programs include, Anti-tau Antibody (VY-TAU01), SOD1 Silencing Gene Therapy (siRNA), FXN Gene Therapy among others.

About EVC Entravision Communications Corporation

Entravision Communications Corp is a global advertising solutions, media, and technology company. Its operations encompass integrated marketing and media solutions, comprised of television, radio, and digital properties and data analytics services. The company operates in television broadcasting, audio broadcasting, and digital media segments. The Company's digital segment, whose operations are located in Europe, Latin America, Asia, the United States, and Africa. The Company's television and audio operations reach and engage U.S. Hispanics in the United States.

Share on Social Networks: